New method of targeting mutant RAS provides hope for cancer patients

As a 10-year journey comes to fruition, MUSC Hollings Cancer Center researcher John O’Bryan, Ph.D., and colleagues have demonstrated a new therapeutic

Related Keywords

United States ,American ,John Obryan ,Shohei Koide ,Hollings Cancer Center ,University Of South Carolina ,Department Of Veterans Affairs ,Perlmutter Cancer Center At New York University ,American Cancer Society ,Department Of Cell ,Cancer Center ,Johno Bryan ,Molecular Pharmacology ,Experimental Therapeutics ,Medical University ,South Carolina ,Perlmutter Cancer Center ,New York University ,Veterans Affairs ,